• search

Lupin Pharma inks pact with Chester Valley Pharma for Atopiclair

Written by: Staff
|

Mumbai, Mar 3 (UNI) Lupin Pharmaceuticals, Inc (LPI), a wholly owned subsidiary of Lupin Ltd, has entered into an agreement with Chester Valley Pharmaceuticals in the United States to promote Atopiclair Nonsteroidal cream to pediatricians.

The company said under the terms of the agreement, LPI's pediatric sales force will promote Atopiclair Nonsteroidal cream to pediatric prescribers. LPI has created a dedicated national pediatric sales force to promote its third generation cephalosporin, Suprax.

Chester Valley Pharmaceuticals will continue to promote Atopiclair Nonsteroidal Cream to dermatologists and other prescribers. This cream is the first prescription medical device authorised by the US FDA to relieve symptoms of atopic dermatitis and allergic contact dermatitis.

Commenting on the agreement, the company's press release quoting the LPI President Vinita Gupta said, ''We are pleased to enter into this relationship with Chester Valley Pharmaceuticals. We believe that LPI's pediatric sales force will expand the usage of this new product for atopic dermatitis and allergic contact dermatitis among pediatricians.'' Chester Valley Pharmaceutical's President and CEO Bob Moccia said, ''This new relationship with Lupin will permit Chester Valley Pharmaceuticals to focus its recently expanded sales force on the promotion of Atopiclair Nonsteroidal cream and Benziq Gels and Wash to dermatologists.'' UNI SN MJ AW1949

For Daily Alerts
Get Instant News Updates
Enable
x
Notification Settings X
Time Settings
Done
Clear Notification X
Do you want to clear all the notifications from your inbox?
Settings X
X
We use cookies to ensure that we give you the best experience on our website. This includes cookies from third party social media websites and ad networks. Such third party cookies may track your use on Oneindia sites for better rendering. Our partners use cookies to ensure we show you advertising that is relevant to you. If you continue without changing your settings, we'll assume that you are happy to receive all cookies on Oneindia website. However, you can change your cookie settings at any time. Learn more